Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224509 · ClinicalTrials.gov registry record · NA
The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01224509 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 18 participants.
The verdict
NCT01224509, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age.
Interventions
- DRUG Mifepristone
- OTHER Non-treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224509
The ClinicalTrials.gov registry entry for NCT01224509 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mifepristone is the first listed.
NCT01224509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01224509 about?
NCT01224509 is a clinical study titled "The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors". The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age.
What is the current status of trial NCT01224509?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2004-09. Estimated completion is 2005-03.
What interventions are being tested in trial NCT01224509?
The interventions under investigation include: Mifepristone (DRUG), Non-treatment (OTHER).
Who is sponsoring clinical trial NCT01224509?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.